🔗 Share this article

Given that the US proceeds with historic adjustments to its vaccine schedules, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning Covid vaccines during the global health crisis and has focused upon alleged deaths after COVID-19 immunization in her brief position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Health officials had intended to unveil major revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would place the US at odds with much of the world with insufficient data for improved outcomes. This reveal has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the meeting. She was just designated interim head of the FDA’s CDER, the fifth appointee to lead the division this year.

A Shift at the Agency

The acting appointment might represent a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US to become more similar to Denmark's approach, a society with universal health coverage and a population about the population of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – typically the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Background

Høeg has little discernible track record in drug development, regulation or leadership, which has been typical for past heads of the CBER. She has been employed at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that previous people who ran CBER have had.”

The drug center has an enormous portfolio at the agency, she emphasized.

“Everybody just focuses on the new drug program, but the generic program authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one need to be looked after,” Woodcock explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the role, which oversees more than 5,000 personnel. “It’s a enormous management job, if you execute it properly,” the former official concluded.

Response and Contentious Policies

In response to concerns about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among FDA leaders on immunizations, a press secretary responded that the “concerns stem from inaccurate presumptions”.

“Her experience is consistent with the duties of her role,” the spokesperson explained, pointing to the months Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s recently launched priority voucher program, a controversial one-day medication authorization process that allegedly concerned her predecessors. “How are these drugs being picked for this expedited pathway? Who takes the calls?” Dr. Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Overall, he said, “the FDA looks to be trending towards more relaxed regulations of all drugs, except for shots.”

Public History on Vaccines

Concerning vaccines, Høeg has a more documented, if troubling, track record, Howard have noted. She authored a analysis using unverified volunteer-provided data to assess the frequency of myocarditis following COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the new administration featured revising regulations for recently developed shots and ending “non-essential” vaccines, she said after the election on a online show. At the FDA, Høeg has reportedly suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She is an complete dogmatist who starts off with her beliefs and works backwards to retrofit the science in a extremely disingenuous, fraudulent fashion,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|